FDA OKs First Oral Therapy for Spinal Muscular Atrophy
The US Food and Drug Administration (FDA) has licensed risdiplam (Evrysdi, Roche and PTC Therapeutics) for the medication of adults and adolescence now not now not up to 2 months weak who luxuriate in spinal muscular atrophy (SMA). This marks…